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Background: Contrast enhanced cardiovascular magnetic resonance (CMR) with T1 mapping enables quantification
of diffuse myocardial fibrosis. Various factors, however, can interfere with T1 measurements. The purpose of the
current study was to assess the effect of co-medication with a typical protein binding drug (Ibuprofen) on T1 values
in vitro and in vivo.
Methods: 50 vials were prepared with different concentrations of gadobenate dimeglumine, Ibuprofen and human
serum albumin in physiologic NaCl solution and imaged at 1.5T with a spin echo sequence at multiple TRs to
measure T1 values and calculate relaxivities. 10 volunteers (5 men; 31±6.3 years) were imaged at 1.5T. T1 values for
myocardium and blood pool were determined for various time points after administration of 0.15mmol/kg
gadobenate dimeglumine using a modified look-locker inversion-recovery sequence before and after administration
of Ibuprofen over 24 hours. The partition coefficient was calculated as ΔR1myocardium/ΔR1blood, where R1=1/T1.
Results: In vitro no significant correlation was found between relaxivity and Ibuprofen concentration, neither in
absence (r=−0.15, p=0.40) nor in presence of albumin (r=−0.32, p=0.30). In vivo there was no significant difference
in post contrast T1 times of myocardium and blood, respectively and also in the partition coefficient between exam
1 and 2 (p>0.05). There was good agreement of the T1 times of myocardium and blood and the partition
coefficient, respectively between exam 1 and 2.
Conclusions: Contrast enhanced T1 mapping is unaffected by co-medication with the protein binding substance
Ibuprofen and has an excellent reproducibility.
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It has been demonstrated that T1 time as measured
by T1 mapping by means of cardiovascular magnetic
resonance (CMR) correlates with histologically proven
fibrosis.[1] Post-contrast T1 values have been shown to
be altered in various cardiac diseases such as systemic
lupus erythematosus [2], cardiac amyloidosis [3], chronic
aortic regurgitation [4], adult congenital heart disease
[5], and diabetic cardiomyopathy [6,7]. Since the concen-
tration of the gadolinium based contrast agent is directly* Correspondence: nadine.kawel@gmx.de
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reproduction in any medium, provided the orrelated to the difference between pre-contrast and post-
contrast reciprocal values of T1 (ΔR1) and based on the
assumption of a steady state of the concentration of the
gadolinium based contrast agent between the extracellu-
lar space and the blood pool, the extracellular volume
fraction (ECV) which is directly related to the collagen
content can be quantified by calculating the ratio of pre-
and post-contrast reciprocal values of T1 measured in
blood and myocardium corrected for the hematocrit
[ECV = ΔR1myocardium/ΔR1blood * (1-hematocrit)].
Calculation of the partition coefficient (Lambda) is iden-
tical to the ECV except that it is not corrected for the
hematocrit. Messroghli et al. demonstrated a correlationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fied by histologic analysis.[8] Wong et al. recently identi-
fied the predictive value of expansion of the extracellular
matrix as calculated by ECV and all cause mortality as
well as a composite end point of death, cardiac trans-
plant and left ventricular assist device. [9] T1 mapping
and calculation of the imaging biomarker ECV and the
partition coefficient, respectively is a promising tech-
nique that might replace invasive myocardial biopsy in
diagnosing diffuse myocardial fibrosis and might be a
useful tool to monitor therapy. Advantages of CMR T1
mapping as compared to myocardial biopsy are 1) non-
invasiveness and therefore the possibility to repeat
measurements for treatment monitoring, 2) large mea-
surement volume rather than small biopsy samples and
3) the fact that no ionizing radiation is required.
T1 mapping is technically demanding since technical,
physiological, and biochemical factors can interfere
with T1 measurements. For example renal function as
reflected by glomerular filtration rate is of relevance
[10]. Moreover, contrast material dose, relaxivity, biodis-
tribution, clearance, interaction with plasma proteins,
and interference with co-medication must be taken into
consideration.
It has been demonstrated that both the T1 relaxation
time and the partition coefficient lambda (calculated by
the change in relaxation rate of blood and myocardium)
vary with relaxivity and distribution properties of the con-
trast material [11]. Gadobenate dimeglumine (Gd-BOPTA,
Multihance®) has some weak protein binding capacities
and higher molar relaxivity in plasma/blood as compared
to other extracellular gadolinium based contrast agents
leading to a shorter T1 time [12-14]. Indirectly, rise of
molar relaxivity is linked to protein interaction of the
gadolinium based contrast agent influencing also its distri-
bution with reduction of extravasation or prolongation of
elimination half-time as shown with gadofosveset triso-
dium [15]. Other gadolinium based contrast agents also
have protein binding capacity but to a lesser extent [16].
Hypothetically co-administration of another drug with
a high protein binding capacity might compete with
Gd-BOPTA and reduce its bound fraction, therefore
altering T1 time. It is well known in pharmacology that
albumin binding drugs potentially can interfere with each
other due to this interaction with the binding sites on the
albumin. This can also be explained by the fact, that the
bound fraction (often > 99%) usually is not active while
the non-bound fraction (1%) is active and can extrava-
sate. Both effects might as well play a role when studying
the relaxivity effects with Gd-BOPTA and the T1 map-
ping. From our perspective these potential interactions
must be studied more in detail and are of high clinical
interest, both from a mechanistic understanding but also
clinically speaking.Therefore the aim of this study was to evaluate the
interference of a typical protein binding drug (Ibuprofen)
with Gd-BOPTA with respect to T1 times in-vitro and
in-vivo.
Ibuprofen was chosen since it is a common drug in
widespread use available without prescription and known
to have a high protein binding capacity. Moreover, the
dosage in mg and moles compared to other non-steroidal
anti-inflammatory drugs is quite high.
Methods
In vitro sample preparation
A total of 50 vials were prepared by diluting Gd-BOPTA
(Gadobenate dimeglumine, Multihance, Bracco Imaging,
Milan, Italy), Ibuprofen and human albumin in physio-
logic NaCl solution. The vials contained all combinations
of the following dilutions: Gd-BOPTA corresponding to
Gadolinium concentrations of 0, 2, 4, 8 and 16mmol/l,
Ibuprofen in concentrations of 0, 100mg/l (=0.48mmol/l),
200mg/l (=0.97mmol/l), 400mg/l (=1.94mmol/l) and
1000mg/l (=4.85mmol/l), Albumin in concentrations of 0
and 4g/dl (according to the physiologic concentration of
human serum albumin of adults).
Study subjects
10 volunteers (5 men; mean age ± SD, 31 ± 6.3 years)
were included in the in vivo part of the study. All volun-
teers were healthy subjects without a known cardiovas-
cular disease or systemic conditions and were not on
regular medication. All volunteers had a normal creatin-
ine value indicating a normal renal function and no
signs of a dyslipoproteinemia as assessed by serum elec-
trophoresis and immunfixation for Bence-Jones proteins
in urine. All study participants signed informed consent
in this institution review board approved study.
Image acquisition – in vitro
Samples were placed in a water container and imaged
on a 1.5T clinical magnet (Avanto, Siemens Medical
Solutions, Erlangen, Germany) in order to establish T1
values. Samples were scanned with a coronal 2D spin
echo sequence at multiple TRs with the following para-
meters: TE 6.2ms; bandwidth 781Hz/pixel; slice thick-
ness 10 mm; field of view 300 x 206 mm; matrix 256 x
176; TR 20, 25, 30, 40, 50, 75, 100, 150, 200, 250, 300,
400, 500, 1000, 1500, 2000, 4000 ms.
Image acquisition – in vivo
Volunteers were imaged on a 1.5T magnet (Espree,
Siemens Medical Solutions, Erlangen, Germany). For T1
mapping a modified look-locker inversion-recovery
(MOLLI) sequence was used to acquire images at mid-
ventricular short axis pre contrast and every 5 minutes
between 5 and 60 minutes after intravenous bolus
Figure 1 In vitro experiment: Change in T1-Relaxivity values
with increasing Ibuprofen concentration in presence or
absence of albumin.
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sequence acquired 11 images at different inversion
times using the following scan parameters: TE/TR
1.06ms/2.5ms; flip angle 35°; bandwidth 1002Hz/pixel;
slice thickness 8mm; field of view 340 x 255 mm; matrix
192 x 138; TI initial 100ms; TI increment 80ms.[17]All
volunteers were scanned twice at intervals of 24 hours.
Immediately after the first scan 800mg Ibuprofen
(Irfen®-800 retard, Mepha Pharma AG, Switzerland) was
administered orally and again after 12 hours and 4 hours
prior to the second scan. Ibuprofen was taken at least
30 minutes preprandial or 2 hours postprandial.
Image analysis – in vitro
T1 values were calculated for each sample by a pixelwise
fitting of the signal intensities, directly on the scanner,
by means of a custom reconstruction procedure [18].
The images were then transferred to a personal com-
puter and circular ROIs were drawn on the sections of
the tubes in order to obtain the average T1 values. For
each Gd-BOPTA dilution series, the relaxivity value r1
was calculated as the slope of the linear fitting of the
inverse of the T1 times, obtaining in the end 10 relax-
ivity values for Gd-BOPTA in presence of the different
Ibuprofen concentrations, with and without albumin.
Image analysis – in vivo
In vivo T1 maps were generated using MRmap [19] and
transferred to QMass V.7.2 (Medis Medical Imaging
Systems, Netherlands). Left ventricular endocardial and
epicardial contours were drawn manually while segments
were defined automatically. T1 time was determined for
each segment (American Heart Association segments
7–12 [20]) separately and also calculated for the entire
slice as the mean value of all segments excluding seg-
ments with severely impaired image quality. T1 time of
blood was also measured. Measurements were obtained
in the LV cavity taking care to avoid inclusion of the pap-
illary muscles using a region of interest (ROI) covering
an area of 3–4 cm2. Heart rate correction as it has been
suggested for studies using 3T scanners was not per-
formed since differences for shorter T1 times at normal
heart rates are very small.[21] The partition coefficient
which reflects the change in relaxation rate of myocar-
dium and blood was approximated by ΔR1myocardium/
ΔR1blood, where R1=1/T1 [22].
Statistical analysis – in vitro
Relaxivity values in presence or absence of albumin were
compared by a paired t-test to establish the effect of pro-
tein binding on the relaxivity of Gd-BOPTA. Correlation
between the calculated relaxivity values and Ibuprofen
concentration was evaluated by Pearson’s correlation
coefficient, separately in presence or absence of albumin.Statistical analysis – in vivo
Statistical analysis was performed using PASW (SPSS)
(version 19) and SAS (version 9.2) statistical software. A
p-value <0.05 was considered statistically significant.
The continuous variables, T1 time and lambda, are
expressed as mean ± SD and were compared using
student’s paired t-test for pre contrast values of T1
since data was normally distributed (Kolmogorov-
Smirnov test). A linear mixed-model analysis was per-
formed with the log transformed T1 times for blood
and myocardium to compare T1 time of both exams
after contrast administration. Linear mixed-model ana-
lysis with the partition coefficient was also performed.
Both sets of models evaluated group, time and group-
by-time interaction by study subjects as random effects.
Correlation between T1 times and the partition coeffi-
cient, respectively acquired in exam 1 and 2 was
assessed by calculating the intraclass correlation coeffi-
cient (ICC) using a two-way random model and agree-
ment was assessed by generating Bland Altman plots.
Results
T1-Relaxivity values of the in vitro experiment with Gd-
BOPTA (Figure 1) were found to be significantly differ-
ent in presence (9.24 ± 0.48 mmol-1s-1l) or absence
(7.22 ± 0.28 mmol-1s-1l) of albumin (p=0.001). However,
no significant correlation was found between relaxivity
and Ibuprofen concentration, neither in absence (R=−0.15,
p=0.40) nor in presence of albumin (R=−0.32, p=0.30).
In the in vivo part of the study of 1560 myocardial seg-
ments evaluated (6 segments per slice at 13 time points
in 10 subjects at 2 exams), 10 segments (0.6%) had to be
excluded from analysis related to severely impaired
image quality. Mean values ± SD of the in vivo part are
shown in Table 1. Pre contrast T1 times for myocardium
and blood were not significantly different between exam
1 and 2 (p>0.05). Linear mixed model analysis did not
show a group difference between exam 1 and 2 for post
Table 1 Mean T1 times of myocardium and blood and the partition coefficient (lambda)
T1 myocardium (ms) T1 blood (ms) Lambda
min Exam 1 Exam 2 Exam 1 Exam 2 Exam 1 Exam 2
Pre 1011 ± 32 1002 ± 48 1526 ± 64 1547 ± 58
5 301 ± 16 308 ± 22 148 ± 16 155 ± 24 0.382 ± 0.03 0.386 ± 0.04
10 353 ± 21 367 ± 20 199 ± 25 206 ± 20 0.420 ± 0.04 0.410 ± 0.03
15 389 ± 23 367 ± 20 255 ± 24 234 ± 21 0.416 ± 0.03 0.409 ± 0.03
20 411 ± 26 403 ± 23 246 ± 29 253 ± 23 0.423 ± 0.03 0.411 ± 0.03
25 432 ± 27 425 ± 18 265 ± 30 272 ± 23 0.424 ± 0.03 0.411 ± 0.03
30 450 ± 22 445 ± 16 283 ± 31 290 ± 23 0.426 ± 0.03 0.419 ± 0.03
35 465 ± 25 460 ± 15 300 ± 33 306 ± 24 0.434 ± 0.03 0.428 ± 0.03
40 475 ± 22 479 ± 21 315 ± 33 321 ± 25 0.442 ± 0.04 0.440 ± 0.04
45 488 ± 27 500 ± 17 329 ± 35 338 ± 26 0.444 ± 0.03 0.432 ± 0.03
50 502 ± 27 509 ± 18 344 ± 37 351 ± 28 0.446 ± 0.04 0.440 ± 0.04
55 513 ± 26 525 ± 14 358 ± 38 364 ± 29 0.449 ± 0.04 0.431 ± 0.04
60 524 ± 25 537 ± 16 373 ± 38 379 ± 31 0.454 ± 0.04 0.432 ± 0.04
min = time after contrast administration.
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tion coefficient. Mean T1 times of myocardium and
blood and also the mean partition coefficient increased
over time (p<0.001) between 5 and 60 minutes after con-
trast administration. The mean increase of the partition
coefficient between 5 and 60 minutes after contrast
administration was 19% (exam 1) and 12% (exam 2),
respectively.
The ICC for measurements of T1-time of myocardium
and blood, respectively was 1.0 and for the partition
coefficient it was 0.82. Bland Altman plots demonstrate
a good agreement for the measurements obtained in
both exams (Figure 2).
Discussion
We studied the effect of co-medication with a typical
protein binding drug (Ibuprofen) on contrast enhanced
T1 mapping. Most important findings can be summar-
ized as follows: 1.) Ibuprofen did not significantly affect
T1 times of myocardium and blood when using a gado-
linium based contrast agent with protein binding cap-
acity (Gd-BOPTA) 2.) Correlations of T1 times of
myocardium and blood and partition coefficient between
exam 1 and 2 were excellent.
Injected intravenously the extracellular gadolinium
based contrast agent Gd-BOPTA is known to have a
transient and weak interaction with plasma proteins,
mainly human serum albumin (HSA) [23]. The aromatic
tail of Gd-BOPTA enables binding to hydrophobic
pockets on the HSA surface [24]. Bound to HSA, the
Gd-BOPTA molecule has a lower molecular tumbling
rate and a longer rotational MR correlation time resulting
in an increased relaxivity [25]. Relaxation rate increasesexponentially with increasing HSA concentration in a
physiological range [24]. The protein bound fraction of
Gd-BOPTA is only about 10% [12].
We hypothesized that the protein bound fraction
might be smaller and subsequently relaxivity lower
resulting in longer T1 times for myocardium and blood
post contrast administration when another drug with
protein binding capacity is administered. Results of the
in vivo and the in vitro part of the study demonstrated
that T1 times were not affected by Ibuprofen. The rea-
son might be a stronger binding to HSA of Gd-BOPTA
compared to Ibuprofen. Moreover, it should be empha-
sized that relaxivity depends on a large variety of dy-
namic and structural factors which in this experiment
could not be further elucidated [26]. In the present case
it seems that inner-sphere water exchange which is the
most important relaxivity influencing factor is definitely
much more affected by ligand-protein interaction than
by drug-drug or drug-protein interaction. Our in vitro
experiments thus confirm, that there is no clear negative
affection of relaxivity even at equimolar concentrations
of Ibuprofen and Gd-BOPTA. Further studies are war-
ranted to better understand the dynamics of water-
exchange besides hydration of gadolinium complexes in
the presence of various protein binding drugs in a pro-
teinous environment. In fact, albumin not only increases
the relaxivity of gadolinium complexes in the blood pool,
but also emerges as a versatile carrier for a long list of
therapeutic and diagnostic agents in pathologies such as
diabetes, cancer, rheumatoid arthritis and infectious dis-
eases [27]. Displacement of drugs from their plasma
binding increases the unbound drug fraction potentially
increasing drug effect or potential toxic effects, so that
Figure 2 Agreement of T1 times of myocardium (A), blood (B) and the partition coefficient (C), respectively between exam 1 and 2.
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of high pharmacological interest. Gadolinium complexes
with a high HSA interaction, at least in theory, could be
used to visualize such effects, presuming that the drug
interferes sufficiently with the Gd-complex – albumin
binding sites, which was not the case in the present
model.
In the current study we further demonstrated an
excellent correlation and good agreement, respectively
between the two exams for pre and post contrast T1
values of myocardium and blood, respectively and the
partition coefficient that makes it a valuable tool for ser-
ial exams and intra-individual comparisons. This result
is in agreement with a study by Messroghli et al. whofound a high reproducibility of pre and post contrast
myocardial T1 times [28].
According to a previous publication, we also detected
a statistically significant increase of the partition coeffi-
cient over time indicating that no equilibrium establishes
between the contrast in the intravascular and the inter-
stitial space presumably related to renal excretion and
distribution into other spaces such as bone and synovial
fluid over the 60min observation time [29]. However, the
increase of the partition coefficient between 10 and
30 min after contrast administration, which would usu-
ally be the time span where T1 mapping would be
acquired in a clinical protocol, was only 0.01. Therefore
the difference might not be clinically relevant.
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for the effect of Ibuprofen on T1 time. Other substances
with high protein binding capacity such as Diltiazem,
Propranolol, Itraconazole or Sufentanil were not evalu-
ated [27]. However, we intended to test a substance that
is easily available without prescription, not harmful to
volunteers and commonly used. Another limitation
might be the fact that we studied the effect of a protein
binding substance on the partition coefficient but not on
the ECV. However, since calculation of the partition co-
efficient and ECV is identical, expect for the fact that
the latter is multiplied by a constant (1-hematocrit), this
should be irrelevant regarding the evaluation of the effect
of Ibuprofen.
Conclusions
In conclusion, contrast enhanced T1 mapping of
Gd-BOPTA is unaffected by co-medication with the pro-
tein binding substance Ibuprofen in vitro and in vivo
and has an excellent reproducibility.
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